Success Story

Abrax Japan licenses technology from Penn

Abrax Japan, a company co-founded by Taku Kambayashi, MD, PhD, Associate Professor of Pathology and Laboratory Medicine at Penn Medicine, entered into an exclusive licensing agreement for certain Penn-owned inventions relating to the therapeutic effects of thymic stromal lymphopoietin (TSLP) developed in Dr. Kambayashi’s laboratory at Penn. Under the terms of the agreement, Abrax Japan secured exclusive global rights to the technology for the treatment and prevention of skin and scalp ailments and disorders including eczema and for the  treatment and prevention of lipid metabolism disorders, including hypercholesterolemia, hypertriglyceridemia, and obesity.

Skip to content